Listed by the USPTO as HUTSON, RICHARD G
Tech Center 1600 • Art Units: 1652 1683
This examiner grants 65% of resolved cases
HUTSON, RICHARD G is assigned to art unit 1652 in tech center 1600 and has 909 resolved cases. The allowance rate is 65.1%, with a median of 1278 days to allowance. The substantial record supports using the outcome data for planning, while the median indicates a prosecution path that may be prolonged.
The interview lift is 52.9%, a strong process signal relative to the 65.1% allowance rate. Practitioners may make interview preparation a central part of response strategy, especially where discussion can identify workable claim distinctions. The listed companies are Novozymes A/S, Massachusetts Institute of Technology, and 10x Genomics Inc. The listed firms are Johnson, Marcou, Isaacs & Nix, LLC, BALLARD SPAHR LLP, and FOLEY & LARDNER LLP.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18349707 | NOVEL CAS13B ORTHOLOGUES CRISPR ENZYMES AND SYSTEMS | Non-Final OA | Massachusetts Institute of Technology |
| 16954032 | CAS12A SYSTEMS, METHODS, AND COMPOSITIONS FOR TARGETED RNA BASE EDITING | Final Rejection | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 18596176 | MODIFIED ENZYMES | Final Rejection | Oxford Nanopore Technologies PLC |
| 18538539 | REVERSE TRANSCRIPTASE VARIANTS FOR IMPROVED PERFORMANCE | Non-Final OA | 10X GENOMICS, INC. |
| 18384537 | FUSION RT VARIANTS FOR IMPROVED PERFORMANCE | Final Rejection | 10x Genomics, Inc. |
| 18065644 | FABRIC AND HOME CARE COMPOSITION INCLUDING A PROTEASE | Non-Final OA | The Procter & Gamble Company |
| 18266787 | CYTOCHROME P450 MONOOXYGENASES AND USES THEREOF | Final Rejection | THE UNIVERSITY OF BRITISH COLUMBIA |
| 18740839 | Method For Improving Mitochondrial Functions | Non-Final OA | TOHOKU UNIVERSITY |
| 18288490 | NOVEL PROTEIN HAVING METHANE OXIDATION ACTIVITY | Non-Final OA | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION |
| 16626396 | NOVEL TYPE VI CRISPR ORTHOLOGS AND SYSTEMS | Final Rejection | President and Fellows of Harvard College |
| 18186443 | COMPOSITIONS AND METHODS FOR CAS9 MOLECULES WITH IMPROVED GENE EDITING PROPERTIES | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18389518 | Subtilase Variants and Compositions Comprising Same | Final Rejection | Novozymes A/S |
| 18547525 | DNASE VARIANTS | Non-Final OA | Novozymes A/S |
| 18263339 | ALPHA-AMYLASE VARIANTS | Final Rejection | Novozymes A/S |
| 18043515 | POLYESTER DEGRADING PROTEASE VARIANTS | Final Rejection | Novozymes A/S |
| 18600046 | MODIFIED O-METHYLTRANSFERASES USEFUL FOR PRODUCTION OF O-METHYLATED PHENOLIC NATURAL PRODUCTS | Non-Final OA | The University of Hong Kong |
| 19008032 | Production Of Non-Native Monounsaturated Fatty Acids In Bacteria | Non-Final OA | Genomatica, Inc. |
| 18255349 | LIQUID ENZYME PREPARATION | Non-Final OA | AMANO ENZYME INC. |
| 18538262 | ALTERED CYTIDINE DEAMINASES AND METHODS OF USE | Final Rejection | ILLUMINA, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy65.1% of resolved applications examined by Richard G Hutson were allowed (909 resolved cases), compared with 53.5% across Art Unit 1652 over the last five years.
This examiner's interview lift is +52.9 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Richard G Hutson took 1,278 days on average from filing to allowance.
Richard G Hutson examines applications in Art Unit 1652 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
